Jade Biosciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Jade Biosciences Inc 's ROA in the second quarter of 2026?
Jade Biosciences Inc recorded a cumulative net loss of $-153 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -45.61%.

However, within the Healthcare sector 592 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4030, from total ROA ranking in the first quarter of 2026 at 4853.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	110.8 %	312.84 %	352.99 %	37.21 %	25.14 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-153	-130	-127	-101	-93
Return On Assets (TTM)	-45.61 %	-47.32 %	-59.71 %	-69.47 %	-70.4 %
JBIO's Total Ranking	# 4030	# 4853	# 4208	# 4344	# 4511
Total Assets (TTM) in million	472	319	350	202	224
Seq. Total Assets Change	47.8 %	-8.68 %	72.77 %	-9.61 %	189.46 %
Seq. Net Income Change	-	-	-	-	-

JBIO's 5 Years Annual ROA >> Back to JBIO Management Effectiveness >> Compare JBIO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 263
Sector	# 593
Overall	# 3957

Return On Assets Statistics
High	Average	Low
-2.61 %	-51.89 %	-96.59 %
(Dec 31 2021)		(Mar 31 2025)

Financial Statements
Jade Biosciences Inc 's Assets	$ 472 million	JBIO's Balance sheet
Jade Biosciences Inc 's Income	$ -56 million	Quarterly JBIO's Income Statement
JBIO's Income by Division		See JBIO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	336.56 %	-35.58 %	-7.68 %	-23.17 %	-
Total Assets in million	350	80	124	135	175
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-127	-70	-76	-52	-23
Annual Return On Assets	-36.43 %	-86.9 %	-60.72 %	-38.23 %	-13.09 %

JBIO's 5 Years Annual ROA >> Back to JBIO Management Effectiveness >> Compare JBIO ROA to its Competitors

More Return On Assets Ratios
JBIO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
JBIO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for JBIO's Competitors
Subscribers only: Roa for Jade Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for JBIO's Customers

You may also want to know
JBIO's Roi	JBIO's Inventory Turnover Ratio	JBIO's Growth Rates	JBIO's Dividend Comparisons
	JBIO's Profitability Ratios	JBIO's Asset Turnover Ratio	JBIO's Dividend Growth
JBIO's Roe	JBIO's Valuation Ratios	JBIO's Financial Strength Ratios	JBIO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T18:21:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.